Canaccord lowered the firm’s price target on Staar Surgical to $41 from $43 and keeps a Hold rating on the shares. The firm said they delivered an overall solid Q2 but concerns remain on the macro impact to demand.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STAA:
- Staar Surgical Q2 Financial Results and 2024 Outlook Webcast
- STAA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Staar Surgical price target raised to $53 from $46 at BTIG
- Staar Surgical downgraded to Underweight from Equal Weight at Morgan Stanley
- Staar Surgical Enhances Governance and Growth Strategy